Sulfamethoxazole-Trimethoprim Prophylaxis in Pediatric Oncology Patients With Glucose-6-Phosphate Dehydrogenase Deficiency-Reference-Cited by-同舟云学术

Sulfamethoxazole-Trimethoprim Prophylaxis in Pediatric Oncology Patients With Glucose-6-Phosphate Dehydrogenase Deficiency

Published:2024-08-07 Issue: Volume: Page:
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Stone Rachael M.¹^ORCID,Haidar Cyrine E.¹,Kornegay Nancy M.¹,Barker Patricia J.¹,Karol Seth E.²,Wolf Joshua³,Hankins Jane S.⁴,Relling Mary V.¹,Crews Kristine R.¹^ORCID

Affiliation:

1. Department of Pharmacy and Pharmaceutical Sciences

2. Department of Oncology

3. Department of Infectious Diseases

4. Department of Global Pediatric Medicine and Hematology, St. Jude Children’s Research Hospital, Memphis, TN.

Abstract

We sought to determine whether Pneumocystis jirovecii pneumonia prophylaxis with sulfamethoxazole-trimethoprim (SMX-TMP) is associated with an increased frequency of acute hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency versus non-G6PD-deficient controls in a pediatric oncology population. There was no statistically significant difference in change in hemoglobin or transfusion requirements after starting SMX-TMP between groups. These findings suggest no increased risk of acute hemolytic anemia with SMX-TMP administered at prophylaxis doses in patients with G6PD deficiency.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference7 articles.

1. Favism and glucose-6-phosphate dehydrogenase deficiency.;Luzzatto;N Engl J Med,2018

2. Glucose-6-phosphate dehydrogenase deficiency.;Luzzatto;Hematol Oncol Clin North Am,2016

3. Incorporating G6PD genotyping to identify patients with G6PD deficiency.;Morris;Pharmacogenet Genomics,2022

4. Expanded Clinical Pharmacogenetics Implementation Consortium guideline for medication use in the context of G6PD genotype.;Gammal;Clin Pharmacol Ther,2023

5. Pneumocystis jirovecii pneumonia in children with hematological malignancies: diagnosis and approaches to management.;Mantadakis;J Fungi (Basel),2020